Purely speculating, but I suspect it's a question of...
safety, rather than efficacy.
The FDA likely felt there was sufficient safety data - based on the current trial's interim, as well as previous trials - to grant the request. 'First do no harm' extends to the FDA, too. I would resist the temptation to view it as an acknowledgement of efficacy. The trial data is still blinded and in vitro outcomes aren't nearly enough.
To continue my speculation, I'm guessing that persons with a relationship to the company (shareholders, or other arm's length parties) had a friend/family member stricken with Covid and appealed to the company.